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(2) Wong et al. disapprove of our proposal for this modiﬁed AKI
classiﬁcation that uses the cut-off value of serum creatinine
of 1.5 mg/dl, to categorize patients with AKI stage 1. In our
opinion, as well as that of others, the use of a cut-off of
serum creatinine makes perfect pathophysiological sense
because it helps put into perspective the relative increase
in serum creatinine used in the AKIN classiﬁcation. In this
regard, it is clear that a 50% increase in serum creatinine
is markedly dependent on the baseline creatinine value.
In fact, a 50% increase does not have the same signiﬁcance
in a patient with a baseline serum creatinine level of
0.6 mg/dl, compared to that of a patient with a baseline
level of 1.2 mg/dl. In the ﬁrst case, the ﬁnal value is
0.9 mg/dl, which despite the 50% raise still represents a
relatively preserved glomerular ﬁltration rate. By contrast,
in the second case the ﬁnal value is 1.8 mg/dl, which
corresponds to a very low glomerular ﬁltration rate, indi-
cating the presence of signiﬁcant organ failure. If we trans-
late this example to the liver using serum bilirubin as
marker of liver function, it is clear that a 50% increase in
serum bilirubin does not represent the same degree of liver
failure when the ﬁnal value of bilirubin is 3 mg/dl or 12
mg/dl.
(3) Another argument used by Wong et al. to refute our
classiﬁcation based on a cut-off level of serum creatinine
of 1.5 mg/dl, is that it could result in late diagnosis of
AKI and delayed interventions. We disagree with this
interpretation of our ﬁndings. Nowhere in our study it
is stated that patients with AKI stage 1A should not be
treated for AKI. In fact, all patients diagnosed at AKI
stage 1A (serum creatinine <1.5 mg/dl) were investigated
to determine the cause of AKI and received immediate
treatment, whenever a cause of AKI was identiﬁed.
Moreover, with our approach, the majority of patients
(77%) were diagnosed at AKI stage 1, while only 12%
were diagnosed at stage 3, which clearly seems to indi-
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We really appreciate the interest ofWong and colleagues, from the
North American Consortium in the Study of End-Stage Liver
Disease (NACSELD) group, on our study published in the Journal
of Hepatology in late 2013 [1]. As a research group interested in
kidney dysfunction in cirrhosis, we share the concerns of our
American colleagues about improving the diagnosis and
management of kidney dysfunction in cirrhosis. Needless to say,
we agree on their comments about the need for improving the
interpretation of the relationship between glomerular ﬁltration
rate and serum creatinine values in women. This is particularly
important in the application of theMELD score for organ allocation
in liver transplantation. We would be willing to join efforts with
our American colleagues to further investigate this issue. That said,
we would like to highlight 4 important issues related to their
letter:
(1) The study of Fagundes et al. [1] was a prospective evaluation
of all patients requiring hospital admission for an acute
decompensation of cirrhosis, during a 26-monthperiod,with
the only exceptions of patientswith large hepatocellular car-
cinoma, previous solid organ transplantation, and those on
renal replacement therapy. Therefore, our study population
included ‘‘all comers’’ to a tertiary hospital. We do not know
whether our results apply to similar populations of patients
with cirrhosis in other tertiary hospitals or to different popu-
lations in other settings. The new classiﬁcation proposed
(categorizing AKI stage 1 in two subgroups-A and B- and
combining stages 2 and 3) was internally validated, but we
obviously stated in the manuscript that it would require
external validation in future studies before it could bewidely
applicable. Nonetheless, it is important to remark that in the
same issue of the Journal, in which our study was published,
Piano et al. reported amazingly similar results in a population
of ‘‘all comers’’ with decompensated cirrhosis, in a tertiary
hospital in Northern Italy [2].Journal of Hepatology 2015 vol. 62 j 739–752 743
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cate that there was no delay in the diagnosis of AKI. By
comparison, ﬁgures reported in a multicenter study per-
formed in several North American hospitals were 48% for
stage 1 and 23% for stage 3 [3]. Moreover, in our study,
progression from stages 1 and 2 to higher stages
occurred in only 22% of patients, a ﬁgure much lower
than the 44% reported in the former study [3]. Therefore,
it appears as though that the use of a 1.5 mg/dl cut-off,
to identify patients with greater kidney dysfunction and
worse prognosis, neither delayed the diagnosis of AKI
nor resulted in a higher rate of progression, compared
to other published reports.
(4) Finally, recent studies from the EASL-CLIF Consortium
highlight the importance of considering, not only kidney
failure, but also the potential co-existence of other organ
failures in patients hospitalized for acute decompensation
of cirrhosis [4]. In this regard, a recent study has shown
that the use of the ACLF classiﬁcation has a higher
predictive accuracy than the AKI classiﬁcation in predict-
ing 28-day and 90-day mortality in cirrhosis [5]. There-
fore, these results suggest that the ACLF classiﬁcation
should be used in patients with cirrhosis hospitalized
for acute decompensation to assess prognosis and also
guide speciﬁc therapies aimed at improving function of
multiple organs.
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A cut-off creatinine value of 1.5 mg/dl for AKI: sometimes ‘‘the
question’’ does not concern ‘‘the being’’, but ‘‘the meaning’’
To the Editor:
We want to thank Wong et al. for their interest in our study pub-
lished in 2013 in the Journal of Hepatology regarding the applica-
tion of acute kidney injury network (AKIN) criteria in the
diagnosis of acute kidney injury (AKI) in patients with cirrhosis
and ascites [1]. In their letter Wong et al. express their concern
about the use of a cut off serum creatinine (sCr) of 1.5 mg/dl in
the diagnosis of AKI in patients with cirrhosis, in particular in wo-
men. They reported that in hospitalized patients with cirrhosis
and bacterial infections, patients with AKI and a peak sCr
<1.5 mg/dl had a poor survival than patients without AKI. These
results are interesting and emphasize that in the setting of bacte-
rial infections mild impairment of renal function may be associ-
ated with poor short-term outcome. However, let us summarize
the development of the application of AKI criteria in patients with
cirrhosis. After the appearance of the AKIN criteria, a working
party of specialists from multiple disciplines proposed summary
statements for the classiﬁcation of renal dysfunction in cirrhosis,
including the AKIN classiﬁcation [2]. However, as hepatologists,
we have used for several years our own deﬁnition of acute renal
failure, achieving relevant results in its prevention and treatment
[3]. Thus, the International Club of Ascites proposed to compare
our own diagnostic criteria of acute renal failure with the AKIN
criteria in terms of prognostic accuracy, rather than to accept
uncritically the latter [4]. Thus, our prospective clinical study
was speciﬁcally aimed to address this relevant issue. Now, let us
to explain better the main observations reported in our
manuscript, since it appears they have been misunderstood. First
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